Please login to the form below
Targovax appoints chief financial officer
Dr Erik Digman Wiklund succeeds Oystein Soug
Targovax has appointed Dr Erik Digman Wiklund as its new chief financial officer from April this year, succeeding Oystein Soug who became the firm's chief executive officer in November 2016.
Dr Wiklund joins the Oslo, Norway-based immuno-oncology specialist from Aker Biomarine Antarctic, where he served as director of product innovation.
He also brings experience from cancer biotech Algeta ASA, and management consulting expertise from McKinsey & Company's pharma and healthcare practice.
Soug said: “We are delighted to announce the appointment of Erik as our new chief financial officer.
“He has an impressive track record in commercial and operational roles in the biotechnology industry, combined with a strong scientific background.
“Erik's breadth of expertise will be key as we approach a number of important milestones in 2017 and 2018 within our innovative clinical pipeline, designed to help patients' own immune system to fight cancer.”
Featured jobs
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Business Director
-
Competitive Salary Offered
-
Account Director, Medical Education
-
Salary TBC
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Account Director
-
Competitive Salary Offered
-
Senior Medical Writer
-
Salary TBC
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
-
Medical Writer
-
Salary TBC
- Global Business Development Director – Health Education
-
excellent commission
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
-
Account Manager / Account Director
-
Competative
-
Associate Director
-
£75, 000-90, 000
-
Senior Account Manager
-
Competitive Salary Offered
Subscribe to our email news alerts
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- Novartis forges AI alliance with Oxford University
- FDA adcomm split on Sanofi’s type 1 diabetes drug
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Essential collaboration skills training for pharma and healthcare teams launched by Dovetail.
- Evenity back on track with FDA panel blessing in osteoporosis
PMHub
Havas Life Medicom
We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...
Latest intelligence
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Healthcare leaders in the European Union should begin preparing for a breakthrough now...
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
- Digital applications are transforming the market access landscape
- Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Quick links
Infographics
